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Abstract
Background:  Prospective investigations of complete decongestive lymphatic physiotherapy
(CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these
interventions for the initial reduction of edema and long-term maintenance of limb volume in
lymphedema. However, CDPT demands substantial time and effort from patients to maintain these
benefits; the treatments are not always well-accepted, and patients may suffer from a deterioration
in quality-of-life or a time-dependent loss of initial treatment benefits. A new device designed for
home use by the patient, the Flexitouch™, has been developed to mechanically simulate MLD. We
have undertaken a prospective, randomized, crossover study of the efficacy of the Flexitouch™,
when compared to massage, in the self-administered maintenance therapy of lymphedema.
Methods: A prospective, randomized, crossover study of maintenance therapy was performed in
10 patients with unilateral breast cancer-associated lymphedema of the arm. Each observation
phase included self-administered treatment with the Flexitouch™ or massage, 1 hour daily for 14
days, respectively, followed by crossover to the alternate treatment phase. Each treatment phase
was preceded by a 1 week treatment washout, with use of garment only. The sequence of
treatment was randomly assigned. The potential impact of treatment modality on quality of life was
assessed with serial administration of the SF-36.
Results: Statistical analysis disclosed that the order of treatment had no outcome influence,
permitting 10 comparisons within each treatment group. Post-treatment arm volume reduced
significantly after the Flexitouch™, but not after self-administered massage. The patients' mean
weight decreased significantly with Flexitouch™ use, but not with massage. The Flexitouch™
device was apparently well-tolerated and accepted by patients. Serial SF-36 administration showed
no deterioration in physical or psychosocial scores compared to baseline measurements; there
were no statistical differences in scores when the two treatment modalities were compared.
Conclusion: This short-term prospective evaluation of the Flexitouch™ suggests that the device
may provide better maintenance edema control than self-adiminstered massage in breast cancer-
associated lymphedema. The apparent ease of use and reliability of response to the device suggest
that further broad-scale testing is warranted.
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Background
Acquired disruption of the lymphatic circulation can lead
to either regional or generalized accumulation of intersti-
tial fluid, known as lymphedema [1]. Among the pre-
dicted 200,000 patients who develop breast cancer
annually [2], conservative estimates dictate that 15–20%
will ultimately develop secondary lymphedema of the
upper extremity [3,4]. The cumulative incidence of
lymphedema appears to increase with each year after sur-
gery [5]. The advent of arm lymphedema after breast can-
cer therapies engenders severe psychological and physical
morbidity [6-8]. Lymphedema affects social relations, and
undermines body image and self-esteem [9].
Complete decongestive physiotherapy (CDPT), a com-
bined treatment program that incorporates manual
lymph drainage, multi-layer short-stretch bandaging,
exercise and skin care, has been recommended by a con-
sensus panel of experts [10] and is considered to be the
standard approach to lymphedema management [11-13].
Various of the elements of CDPT, while costly and labor-
intensive [14], have demonstrable efficacy, with reported
initial reductions of the measured excess limb volume
that approximate 50% [15,16]. Nevertheless, despite the
documented efficacy of initial, intensive CDPT in the
hands of the trained therapist, it has been observed that
the most important factor to influence the long-term
impact of lymphedema interventions is the patient's sub-
jective response to the management variables [17,18]. The
time-consuming, labor-intensive, and repetitive nature of
the treatment strategies pose difficulty and set the stage for
poor, or incomplete, patient compliance [19]. Thus, the
chronic response to physiotherapeutic lymphedema inter-
ventions, once patient self-management supervenes, is
often characterized by a time-dependent loss, to varying
degrees, of the beneficial effects of the short-term inten-
sive interventions undertaken by medical personnel
[15,16]. This treatment recidivism likely reflects the com-
bined influences of patient inefficiency with the demand-
ing techniques of manual lymphatic drainage and
bandaging, and diminished compliance with self-man-
agement strategies.
Optimal management may have the capacity to slow the
inexorable tendency of chronic lymphedema to progress,
and may forestall or eliminate many of the recognized
complications of the disorder, including recurrent soft-tis-
sue infection and chronic fibrosis [10]. To this end, we
have prospectively evaluated the potential benefit of a
Schematic of the study protocol Figure 1
Schematic of the study protocol. There was a randomized assignment to Group I or II. During the washout periods, treatment 
was limited to the daily use of a compressive garment, with manual lymphatic drainage or other intervention. The vertical 
arrows indicate the times at which volumetry was performed by circumferential measurements of the limbs. The SF-36 was 
administered before and after each of the 14 day treatment phases.BMC Cancer 2006, 6:84 http://www.biomedcentral.com/1471-2407/6/84
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new approach to the maintenance phase of self-manage-
ment in breast cancer-associated lymphedema.
The Flexitouch™ is a lightweight, portable device for home
use that has been bio-engineered to closely simulate the
effects of optimally performed manual lymphatic drain-
age. The device has been commercially available in the
United States since June of 2002, when the Flexitouch™
system received 510 K clearance from the Food and Drug
Administration. The current investigation was designed to
evaluate the relative efficacy of the Flexitouch™, when
compared to standard measures, in the maintenance self-
management of breast cancer-associated lymphedema.
Methods
Design of the trial
A prospective evaluation of the Flexitouch™ in the main-
tenance management of breast cancer-associated lymphe-
dema was undertaken in a prospective, randomized,
crossover study. The investigation was undertaken from
December 2003 through June 2004 and was approved by
the Institutional Review Board of Stanford University. The
study design is schematized in Figure 1.
Patients
Patients with lymphedema of the upper extremity after
surgical and/or radiotherapeutic interventions for breast
carcinoma were eligible for enrollment. Recruitment was
undertaken from the population of patients who pre-
sented to the Stanford Center for Lymphatic and Venous
Disorders. Written informed consent was obtained from
all participants.
Inclusion and exclusion criteria
To be eligible for enrollment, a subject was required to
have evidence of unilateral, breast cancer-associated
lymphedema, with an increase of at least 10% in the
measured volume of the affected arm when compared
with the contralateral, normal limb. All subjects were
required to have completed an initial treatment phase of
limb volume reduction through intensive decongestive
physiotherapy administered by a trained physiotherapist.
A minimum of 30 days must have elapsed following the
completion of initial treatment, which was required to
include instruction in self-administered, maintenance
simple manual lymphatic massage and the subsequent
use of a properly fitted compression garment.
Exclusion criteria included the presence of any of the fol-
lowing: bilateral lymphedema of the upper extremity;
active cancer; active infection; clinical evidence of venous
obstruction or active thrombophlebitis; pulmonary
edema; congestive heart failure; a history of pulmonary
embolism; or the presence of any other relative contrain-
dication to the use of the lymphedema treatment modali-
ties employed in this investigation.
Treatment allocation
Once enrolled in the study, subjects were allocated ran-
domly, in equal numbers, to begin treatment with either
the experimental approach (daily use of the Flexitouch™)
or with use of standard treatment measures (compression
garment plus daily self-administered massage). Cross-
over to the alternate arm of therapy occurred in each
enrolled patient after the designated observations and
interval treatment washout had been completed. All study
personnel responsible for patient observations and for
data analysis were blinded to the subjects' treatment sta-
tus, and patients were specifically instructed to refrain
from discussing the particulars of their interval treatment
status with the study personnel.
Treatment methods
Patients were instructed in the standard, self-administered
use of the Flexitouch™. The device provides 1–3 seconds
of mild pressure that moves continuously through the
device during an individual treatment. In theory, the
device design should, by analogy to the purported mech-
anisms of manual lymphatic drainage, encourage excess
interstitial fluid to follow existing pathways of lymph
efflux from the trunk to regain access to the central circu-
lation,. The device features a two-phase preparation and
drainage program. The Flexitouch™ is comprised of an
electronic controller unit, utilized in concert with special-
ized garments worn on the trunk and the affected upper
extremity (Figure 2).
The patented garments include separate trunk and limb
components that, when combined, consist of up to 32
separate chambers. The Flexitouch garment utilizes a pro-
prietary composite of laminated materials that deliver var-
iable stretch during inflation. This stretch is designed to
simulate a therapist's hand movements during manual
The figure depicts the unilateral Flexitouch™ garment as it is  applied to the patient (A) Figure 2
The figure depicts the unilateral Flexitouch™ garment as it is 
applied to the patient (A). The controller unit and connecting 
hoses are seen in panel B.BMC Cancer 2006, 6:84 http://www.biomedcentral.com/1471-2407/6/84
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lymphatic drainage. The device delivers brief applications
(1–3 seconds) of mild pressure in a continuously moving,
rhythmic work-and release-action that is repetitively
applied in each section. No two chambers are ever fully
inflated at the same time.
The inflatable chambers of the garment, constructed of
distensible fabric, connect to the controller unit by tubing
harnesses. In the initial, lymph preparation phase, a mod-
est gradient of pressure is applied to the trunk to prepare
for, and direct, the augmented flux of lymph; thereafter,
lymph drainage of the affected extremity is accomplished
by concerted cycles of pressure applied sequentially to the
limb and the trunk.
For the conventional treatment phase of the trial, self-
administered massage and use of elastic compression gar-
ments was undertaken as patients had been previously
instructed during the initiation phase of CDPT [16], prior
to enrollment in this trial. Self-administered massage is
advocated as a standard technique in the maintenance
management of chronic lymphedema, with a demon-
strated capacity to sustain at least a major component of
the benefits derived from the active therapeutic interven-
tions undertaken with a trained physiotherapist [16]. The
use of any additional management strategies was prohib-
ited during active participation in the trial.
Treatment regimens
The active treatment phases were comprised of mainte-
nance therapy with the Flexitouch™ alone or with self-
administered massage alone, respectively, as an adjunct to
the daily use of the compression garment. Each treatment
modality was utilized for one hour daily during 14 con-
secutive days of treatment. Each phase of active treatment
was preceded by a 1 week treatment washout, with use of
the garment alone (no self-administered massage). The
sequence of treatment was randomly assigned; the initial
modality of therapy was followed, after a second washout
phase, by crossover to the alternate treatment modality.
Measurements and assessments
All outcomes measure and assessments were accom-
plished by medical personnel trained and experienced in
the objective assessment and treatment of lymphedema.
Limb volume measurements
Limb volume was calculated by a validated, indirect vol-
ume measurement that utilizes surface measurements and
a simplified formula derived from the formula for a frus-
tum (truncated cone) [20]. This approach has been dem-
onstrated to have excellent intra- and inter-observer
reliability, and to yield results that are statistically indis-
tinguishable from the water displacement method,
accepted by many, but not all, as the 'gold standard' [21].
Both arms were measured at each time point. Serial meas-
urements were performed using gauged tape to ensure a
uniform stretching force. Limb circumferences were meas-
ured at axial intervals of 4 cm, beginning with an initial
measurement at the radial styloid. For each patient, abso-
lute limb volume was expressed in milliliters (ml). In
addition, the volume of the edematous arm was expressed
as a ratio to the volume of the contralateral, normal arm
(VolumeLymphedema/VolumeNormal × 100%).
Quality of life assessment
The SF-36 was serially administered to each enrolled
patient, before and after each phase of active treatment.
The SF-36 is a validated, generic instrument to assess, in
broad terms, the impact of disease and its management
upon various categories of psychosocial function [22].
This instrument has previously, successfully been applied
to study of breast cancer-associated lymphedema [23].
Data analysis
In this study, continuous variables were statistically com-
pared using analysis of variance, paired and unpaired t-
test analysis (α = 0.05) and multiple regression analysis.
For the sample size of the cohorts in this study and the pri-
mary endpoint of volume response, the statistical analysis
had a power of 0.95 for an alpha = 0.01.
Results
Patient characteristics
Eleven (11) patients were approached for potential inclu-
sion in this study. Consecutively presenting breast cancer
survivors with unilateral upper extremity lymphedema
were informed of the study at the time of their presenta-
tion to the Stanford Center for Lymphatic and Venous
Disorders. Ten of these patients, all female, were enrolled
in this prospective investigation.
The patient ages ranged from 54 to 78 years (60 ± 7 [mean
± SD]. For these patients, the duration since initial cancer
therapy ranged from 36–288 months (103 ± 87 months).
Onset of unilateral arm swelling was noted at 34 ± 34
months prior to enrollment in the study (range, 1–99
months). Initial cancer staging data was available for 8 of
the 10 subjects: 2 initially presented with Stage I disease,
2 with Stage II and 3 with Stage III. Seven of the 10 sub-
jects had undergone adjunctive radiotherapy.
There was an identical incidence of right- and left-sided
involvement (5 subjects each) in this cohort. The mean
pre-treatment body weight was 75 ± 12 kg (range, 58–83
kg). Hypertension (both systolic and diastolic) was preva-
lent in among the enrolled patients: the mean systolic
pressure was 139 ± 14 mm Hg (120–167 mm Hg) and the
mean diastolic pressure was 86 ± 7 mm Hg (80–95 mm
Hg).BMC Cancer 2006, 6:84 http://www.biomedcentral.com/1471-2407/6/84
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The effect of treatment modality on limb volume Figure 3
The effect of treatment modality on limb volume. Panels A and B depict the measured volume of the affected limb for each 
patient before and after Flexitouch™ and MLD therapy, respectively. Panel C illustrates the grouped data for each treatment 
phase (mean ± S.D.; * P = 0.002 when compared to pretreatment volume; § P = 0.007 when compared to the response to 
MLD). By multiple regression analysis, treatment status (Flexitouch™ versus massage) was predictive of volume change (P < 
0.02). When controlled for the pre-treatment body weight, the results were unchanged; however, pretreatment arm volume 
was predictive of treatment response (P = 0.008).BMC Cancer 2006, 6:84 http://www.biomedcentral.com/1471-2407/6/84
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Clinical responses
Five patients initiated the clinical evaluation with the Flex-
itouch™ treatment phase and 5 with self-administered
massage, respectively. Statistical analysis disclosed no out-
come influence of the order of treatment, permitting 10
comparisons within each treatment group. Arm volume
Excess volume of the affected arm, expressed as a percentage of the volume of the contralateral, normal arm Figure 4
Excess volume of the affected arm, expressed as a percentage of the volume of the contralateral, normal arm. The effect of 
treatment on the % excess volume, when compared to the contra-lateral arm, was significant for Flexitouch™ but not for MLD 
(mean ± S.D.; *P = 0.0005 when compared to the pretreatment value; § P = 0.003 when compared to response to MLD).BMC Cancer 2006, 6:84 http://www.biomedcentral.com/1471-2407/6/84
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reduced significantly from pre-treatment (Figure 3) after
the Flexitouch™ (mean change, -208 ± 157 ml, P = 0.002)
but not after self-administered massage (+52 ± 106 ml,
NS); when the absolute volume differences following
Flexitouch™ treatment were compared to those following
self-administered massage, the reduction in volume
attained with the device was statistically significant (P =
0.007). The effect of treatment on the % excess volume,
when compared to the contralateral arm, was significant
for Flexitouch™ (pretreatment, 15 ± 7% vs. post-treatment,
12 ± 6%, P = 0.0005) but not for self-administered mas-
sage (pre- and post-treatment, 14 ± 7%, NS) [Figure 4]. As
a corollary effect of partial edema resolution, the patients'
mean weight decreased significantly after Flexitouch™ (-
2.3 ± 1.3 kg, P = 0.0002) but not after self-administered
massage (+0.5 ± 0.9 kg, NS) [Figure 5]. For the sample size
employed in this study and the primary endpoint of vol-
ume response, the statistical analysis had a power of 0.95
for an alpha = 0.01.
The effect of treatment strategy on body weight (mean ± S.D.; *P = 0.0002) Figure 5
The effect of treatment strategy on body weight (mean ± S.D.; *P = 0.0002).BMC Cancer 2006, 6:84 http://www.biomedcentral.com/1471-2407/6/84
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By multiple regression analysis, treatment status (Flexi-
touch™ versus massage) was predictive of volume change
(P < 0.02). When controlled for the pre-treatment body
weight, the results were unchanged; however, pretreat-
ment arm volume was predictive of treatment response (P
= 0.008). The change in limb volume with treatment was
poorly correlated to the change in body weight (r = 0.3).
Quality of life indicators
Serial administration of the SF-36 demonstrated neither
deterioration nor improvement in physical or psychoso-
cial scores when compared to baseline or to those refera-
ble to standard therapy with self-administered massage.
The total scores for the SF-36 were 132 ± 34 (baseline),
133 ± 33 (Flexitouch™), and 131 ± 37 (massage), respec-
tively. Analysis of variance disclosed no statistical differ-
ences.
In addition to the serial administration of the SF-36, sub-
jects were directly queried about their experiences with the
device. The Flexitouch™ treatment phase was, by patient
report, universally well-tolerated and -accepted. No
adverse experiences were reported at the time of follow-
up, or thereafter.
Discussion
With chronic obstructive derangement in the regional
lymphatic circulation, an edematous state ensues that is
characterized, over time, by chronic architectural altera-
tions in the skin and supporting tissues [1,24]. Lymphede-
matous tissues are conceptualized to have a lower oxygen
content, a greater distance between lymph vessels induced
by the interstitial fluid accumulation, impaired lymphatic
clearance, and depressed macrophage function, endowing
these patients with an increased risk of soft tissue infec-
tion [25]. Once established, lymphedema has an inexora-
ble tendency to progress. The concerted effects of
increased interstitial fluid volume and chronic fibrotic
changes expose these patients to substantial functional
impairment, coupled with the psychosocial dysfunction
that emanates from the chronic disease state and the asso-
ciated impairment in body image and self-esteem [26-28].
Although the deleterious consequences of chronic lymph-
edema can be substantially reduced by effective physical
management [10,15], the long-term impact of chronic
decongestive physiotherapy upon lymphedema has not
yet been optimized. While initial, intensive physiothera-
peutic interventions can effectively minimize volume
changes in the edematous limb, concerted self-manage-
ment is required to maintain therapeutic benefits. Patients
can effectively be taught to self-administer manual lym-
phatic drainage, but a gradual diminution in the magni-
tude of the initial therapeutic benefit is predictable [16]. It
is likely that this phenomenon is related to some com-
bined effect of patient inefficiency and a time-dependent
reduction in patient compliance with self-management
techniques. Adjunctive therapies, like intermittent pneu-
matic compression, have proven benefit [29], but may
compound patient difficulty with compliance, since, of
necessity, these adjunctive treatment measures lengthen
the daily requirement for self-management.
In an attempt to improve the impact of maintenance self-
management strategies on chronic lymphedema, we have
undertaken the current study to investigate the relative
efficacy of the Flexitouch™ when compared with a stand-
ard treatment approach (self-administered massage). The
biodesign of the device and its impact on the disease state
confer some distinct theoretical advantages. Because the
Flexitouch™ is bioengineered to closely simulate the
effects of correctly performed simple manual lymphatic
massage, it should theoretically minimize the effect of
improper or inadequate technique upon the treatment
outcome. Furthermore, because the device emphasizes
comfort and minimizes the active participation of the
patient, it should, in principle, optimize compliance.
Indeed, our observations suggest that, even in short-term
use, the device confers therapeutic benefit over that which
can be attained through standard therapy. In addition to
the demonstrable small, but significant, improvement in
edema volume, the statistically significant reduction in
body weight that accompanies the use of the Flexitouch™
serves as an independent confirmation of the added effi-
cacy of this approach for the reduction of edema volume.
While the magnitude of weight loss cannot be entirely
explained by the quantitative reduction in limb edema
volume, the concurrent changes seem to validate the ben-
eficial impact of the Flexitouch™. The phenomenon of
weight loss certainly bears additional investigation in
larger numbers of patients. The current study was not
designed to specifically address this response and, there-
fore, additional study with control of relevant variables
during the treatment phase, such as fluid intake, diet, exer-
cise, and medications, will be required to validate the
observed phenomenon and to address the potential
mechanisms of the therapeutic benefit.
The current, pilot study is limited chiefly by the small
sample size and short duration of the therapeutic inter-
vention. The positive results suggest that further investiga-
tion will be useful. When observed in larger cohorts of
patients, with treatment phases sustained over longer
intervals, it can be anticipated that even more substantial
volume benefits might be demonstrable. In addition,
quality-life-indicators should theoretically have the capac-
ity to detect any favorable impact of streamlined therapy
upon perceptions of the disease state. Finally, it will be
desirable to attempt to demonstrate the theoretical favo-BMC Cancer 2006, 6:84 http://www.biomedcentral.com/1471-2407/6/84
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rable impact of this intervention upon tissue architecture
and other chronic structural consequences of lymphe-
dema. It is well-recognized that lymphedema, with chro-
nicity, occasions the secondary proliferation of
fibroblasts, keratinocytes, and adipocytes, the accumula-
tion of collagen, and the destruction of elastin fibers
within the skin [30]. It has been hypothesized that effec-
tive physiotherapy of lymphedema can diminish or elim-
inate these otherwise inexorable consequences. It is
relevant that, in a recent study of the effect of therapeutic
intervention upon lymphatic filariasis, the institution of
even simple measures to reduce edema possessed the
capacity to ameliorate the histopathological manifesta-
tions of chronic inflammation and fibrosis in punch biop-
sies of the skin [31]. While such direct histological
confirmation may not be as readily derived from a breast
cancer-associated lymphedema population, future, more
extensive studies of the therapeutic potential of the Flexi-
touch™ might realistically incorporate other, more indi-
rect attempts to document an ameliorative effect upon
tissue architecture. Furthermore, evaluation of patients
during more protracted use of the device, if it indeed
enhances treatment outcome while minimizing the incur-
sion of self-management upon the activities of daily liv-
ing, would be predicted to disclose an improvement in
perceptions of psychosocial and physical well-being. The
aggregate benefits to be derived from this device will then
require consideration in relationship to the retail cost of
this device as it is currently marketed (unilateral garment,
US $10,800; bilateral garment, US $12,400).
Conclusion
Short-term prospective evaluation of the Flexitouch™
device suggests that it may provide better maintenance
control of edema volume than simple manual lymphatic
drainage in patients with breast cancer-associated lymph-
edema. The ease of use and reliability of response to the
device suggest that further broad-scale testing is war-
ranted. Economic implications of the treatment choices
will ultimately also be required to assess its relative merits
within the scope of maintenance lymphedema care.
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